Early and late changes in markers of aortic stiffness with breast cancer therapy

Anthracyclines and trastuzumab are well recognised to cause cardiac toxicity. Further to their effects on left ventricular (LV) function, anthracyclines in particular are considered to cause negative arterial remodelling. Whether these changes reverse is unknown. In addition, whether trastuzumab causes specific effects on arterial remodelling is yet undetermined.

[1]  S. Laurent,et al.  Aortic Stiffness Is an Independent Predictor of Primary Coronary Events in Hypertensive Patients: A Longitudinal Study , 2002, Hypertension.

[2]  E. Lakatta,et al.  Elevated Aortic Pulse Wave Velocity, a Marker of Arterial Stiffness, Predicts Cardiovascular Events in Well-Functioning Older Adults , 2005, Circulation.

[3]  M. Chen,et al.  Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics , 2008, Circulation.

[4]  T. Jones,et al.  Assessment of ventricular function and mass by cardiac magnetic resonance imaging , 2004, European Radiology.

[5]  S. Anderson,et al.  Aortic Pulse-Wave Velocity and Its Relationship to Mortality in Diabetes and Glucose Intolerance: An Integrated Index of Vascular Function? , 2002, Circulation.

[6]  M. Haberka,et al.  Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. , 2013, Kardiologia polska.

[7]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[8]  P. Ducimetiere,et al.  Aortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients , 2001, Hypertension.

[9]  A. Wardley,et al.  Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring , 2009, British Journal of Cancer.

[10]  A de Roos,et al.  Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. , 1998, The American journal of cardiology.

[11]  M. Sargon,et al.  Concomitant trastuzumab with thoracic radiotherapy: a morphological and functional study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  K. Keltai,et al.  Doxorubicin selectively suppresses mRNA expression and production of endothelin-1 in endothelial cells. , 2010, Vascular pharmacology.

[13]  Michael S Ewer,et al.  Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. , 2004, Circulation.

[14]  W. Hundley,et al.  Aortic stiffness increases upon receipt of anthracycline chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[16]  C. Gross,et al.  Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. , 2012, Journal of the American College of Cardiology.